Friday, April 5, 2013
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said one cohort of a Phase II non-small-cell lung cancer (NSCLC) study did not meet its primary endpoint. The cohort evaluated MM-121 in combination with Tarceva (erlotinib, Astellas Pharma Inc.) to treat patients with NSCLC whose disease progressed on an anti-EGFR tyrosine kinase inhibitor (EGFR-TKI).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.